Pousse-seringues : attention aux seringues !, Annales Françaises d'Anesthésie et de Réanimation, vol.8, issue.3, p.295, 1989. ,
, Les résultats en matière de santé sont bons mais les dépenses sont élevées, 2017.
Névrites optiques, La Revue de Médecine Interne, vol.31, issue.7, pp.481-485, 2010. ,
Deux cas de sclérose latérale symétrique amyotrophique, Leçons sur les Maladies du Système Nerveux, pp.402-424 ,
Coping et sclérose en plaques, Neuropsychologie de la sclérose en plaques, pp.47-54, 2010. ,
Multiple sclerosis: Geoepidemiology, genetics and the environment, Autoimmunity Reviews, vol.9, issue.5, pp.A387-A394, 2010. ,
A REASSESSMENT OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS, Acta Neurologica Scandinavica, vol.51, issue.2, pp.110-136, 2009. ,
Coûts de la sclérose en plaques en France, Revue Neurologique, vol.170, issue.6-7, pp.432-439, 2014. ,
The place of environmental factors in multiple sclerosis: Genes, environment and the interactions thereof in the etiology of multiple sclerosis, Revue Neurologique, vol.175, issue.10, pp.593-596, 2019. ,
Physiopathologie de la sclérose en plaques, La Presse Médicale, vol.39, issue.3, pp.341-348, 2010. ,
Multiple sclerosis, The Lancet, vol.372, issue.9648, pp.1502-1517, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00996686
The genetics of multiple sclerosis: an up-to-date review, Immunological Reviews, vol.248, issue.1, pp.87-103, 2012. ,
Impact d?une supplémentation en vitamine D sur les fonctions immunitaires et la réponse vaccinale chez des sujets âgés carencés, Nutrition Clinique et Métabolisme, vol.31, issue.3, pp.235-236, 2017. ,
Sclérose en plaques et Vitamine D?Étude prospective d?une cohorte de patients au CHU de Tlemcen, Revue Neurologique, vol.173, p.S126, 2017. ,
Smoking is a risk factor for multiple sclerosis: a metanalysis, Multiple Sclerosis Journal, vol.13, issue.5, pp.610-615, 2007. ,
The Effect of Infections on Susceptibility to Autoimmune and Allergic Diseases, New England Journal of Medicine, vol.347, issue.12, pp.911-920, 2002. ,
Régulation Moléculaire De La Barrière Hémo-Encéphalique, Canada, 2014. ,
Mise au point sur la physiopathologie de la sclérose en plaques, Annals of Physical and Rehabilitation Medicine, vol.54, p.e290, 2011. ,
Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction, Journal of Experimental Medicine, vol.192, issue.3, pp.393-404, 2000. ,
La sclérose en plaques : physiopathologie, thérapeutiques actuelles et futures ,
La sclérose en plaques, 2019. ,
Anatomie pathologique de la sclérose en plaques et des maladies apparentées, La Sclérose en Plaques - Historique, épidémiologie et Pathogénie, pp.139-150, 2019. ,
La sclérose en plaques, Actualités Pharmaceutiques Hospitalières, vol.5, issue.19, pp.14-19, 2009. ,
Sclérose en Plaque ,
Sclérose en plaques du jeune adulte, Actual Pharm. févr, vol.59, issue.593, pp.15-24, 2020. ,
Traitements actuels de la sclérose en plaques, La Presse Médicale, vol.39, issue.3, pp.381-388, 2010. ,
Dorosz -Médicaments de la SEP (I) : Interférons bêta. 37 ème. Maloine, 2018. ,
Évolution et nouvelles perspectives dans la prise en charge thérapeutique de la sclérose en plaques, vol.138, 2015. ,
Actualités thérapeutiques de la sclérose en plaques, La Revue de Médecine Interne, vol.31, issue.8, pp.575-580, 2010. ,
Dorosz -Médicaments de la SEP (IV) : Immunomodulateur polypeptidique. 37 ème. Maloine, 1336. ,
Actualités dans le diagnostic et la prise en charge thérapeutique de la sclérose en plaques, La Revue de Médecine Interne, vol.34, issue.10, pp.628-635, 2013. ,
Suppression of demyelination by mitoxantrone, International Journal of Immunopharmacology, vol.13, issue.7, pp.923-930, 1991. ,
,
Guide des anticorps monoclonaux à usage thérapeutique -Juilllet, 2020. ,
Eau disponible pour l'utilisation, 2017. ,
Place d?un nouvel anticorps monoclonal (natalizumab) dans la stratégie thérapeutique actuelle de la sclérose en plaques, Actualités Pharmaceutiques Hospitalières, vol.4, issue.13, pp.17-22, 2008. ,
Immunosuppresseur (1). 37 ème. Maloine, 2018. ,
Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis, Journal of Central Nervous System Disease, vol.6, p.JCNSD.S14049, 2014. ,
Efficacité à 10 ans du natalizumab dans une cohorte Française de patients avec une sclérose en plaques récurrente-rémittente : cohorte TYSTEN, Revue Neurologique, vol.175, p.S84, 2019. ,
LEMP ou EMP chez une patiente porteuse d?une sclérose en plaques traitée par natalizumab ?, Revue Neurologique, vol.169, p.A107, 2013. ,
Deux nouveaux traitements par voie orale dans la sclérose en plaques rémittente, Revue Neurologique, vol.170, issue.12, pp.721-722, 2014. ,
Dorosz -Médicaments de la SEP (VII) et (VIII). 37ème. Maloine, p.p, 2018. ,
Traitement de la sclérose en plaques : progrès et nouveaux défis, médecine/sciences, vol.29, issue.12, pp.1067-1068, 2013. ,
Fingolimod for Multiple Sclerosis, New England Journal of Medicine, vol.366, issue.4, pp.339-347, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-00617750
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program, Therapeutics and Clinical Risk Management, vol.Volume 13, pp.1423-1437, 2017. ,
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, New England Journal of Medicine, vol.376, issue.3, pp.209-220, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01793440
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, New England Journal of Medicine, vol.376, issue.3, pp.209-220, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01793440
,
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab, Multiple Sclerosis and Related Disorders, vol.43, p.102155, 2020. ,
Acute pancreatitis after ocrelizumab treatment for relapsing remitting multiple sclerosis, Multiple Sclerosis and Related Disorders, vol.45, p.102381, 2020. ,
Neuroprotection et sclérose en plaques : bases et évaluation, p.1 ,
Biologie des récepteurs de l?immunité innée : applications cliniques et thérapeutiques, Revue Francophone des Laboratoires, vol.2010, issue.424, pp.41-51, 2010. ,
Cours d'immunologie « L'immunité innée et l'immunité adaptative »-L2 Pharmacie, 2015. ,
Réponse de l'endothélium microvasculaire à l'inflammation aiguë, Anesth Réanimation. sept, vol.6, issue.5, pp.493-502, 2020. ,
Endothelial Responses in Sepsis, Am J Respir Crit Care Med. 1 août, vol.202, issue.3, pp.361-70, 2020. ,
Modulation of Endothelial Glycocalyx Structure under Inflammatory Conditions, Mediators Inflamm, 2014. ,
Extra-and intracellular innate immune recognition in endothelial cells, Thromb Haemost, vol.98, issue.08, pp.319-345, 2007. ,
Immune Regulation by Microvascular Endothelial Cells: Directing Innate and Adaptive Immunity, Coagulation, and Inflammation, J Immunol. 15 mai, vol.178, issue.10, pp.6017-6039, 2007. ,
, Neutrophil Adhesion and Activation under Flow. Microcirculation, vol.16, issue.1, pp.31-42, 2009.
Selectin-and integrin-mediated Tlymphocyte rolling and arrest on TNF-alpha-activated endothelium: augmentation by erythrocytes, Biophys J. nov, vol.69, issue.5, pp.2131-2139, 1995. ,
The cellular immunology of multiple sclerosis, J Leukoc Biol, vol.65, issue.4, pp.444-52, 1999. ,
Structure and function of the blood-brain barrier, Neurobiol Dis. janv, vol.37, issue.1, pp.13-25, 2010. ,
Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study, J Physiol. oct, vol.429, pp.47-62, 1990. ,
Astrocyte-endothelial interactions at the blood-brain barrier, Nat Rev Neurosci. janv, vol.7, issue.1, pp.41-53, 2006. ,
Leukocyte Infiltration, Neuronal Degeneration, and Neurite Outgrowth after Ablation of Scar-Forming, Reactive Astrocytes in Adult Transgenic Mice, Neuron. juin, vol.23, issue.2, pp.297-308, 1999. ,
Pericytes regulate the blood-brain barrier, Nature, vol.468, issue.7323, pp.557-61, 2010. ,
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE, Nat Immunol. mai, vol.10, issue.5, pp.514-537, 2009. ,
Getting to the site of inflammation: the leukocyte adhesion cascade updated, Nat Rev Immunol. sept, vol.7, issue.9, pp.678-89, 2007. ,
A molecular trio in relapse and remission in multiple sclerosis, Nat Rev Immunol. juin, vol.9, issue.6, pp.440-447, 2009. ,
The blood-brain barrier, chemokines and multiple sclerosis, Biochim Biophys Acta BBA -Mol Basis Dis. 1 févr, vol.1812, issue.2, pp.220-250, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00652656
Angiotensin II Controls Occludin Function and Is Required for Blood-Brain Barrier Maintenance: Relevance to Multiple Sclerosis, J Neurosci. 22 août, vol.27, issue.34, pp.9032-9074, 2007. ,
Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis, Neuropathol Appl Neurobiol, vol.33, issue.1, pp.86-98, 2007. ,
, Sabatier. Les Anticorps Monoclonaux Thérapeutiques -M1 UE 4 Faculté de Pharmacie, 2017.
, Cell Tissue Res. 20 août, vol.339, issue.1, p.269, 2009.
Integrins and Actin Filaments: Reciprocal Regulation of Cell Adhesion and Signaling, J Biol Chem. 28 juill, vol.275, issue.30, pp.22607-22617, 2000. ,
VLA-4 antagonists: Potent inhibitors of lymphocyte migration, Medicinal Research Reviews, vol.23, issue.3, pp.369-392, 2003. ,
Integrin structures and conformational signaling, Current Opinion in Cell Biology, vol.18, issue.5, pp.579-586, 2006. ,
Leukocyte integrins and their ligand interactions, Immunologic Research, vol.45, issue.2-3, pp.195-208, 2009. ,
,
Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords?, Immunology, vol.116, issue.3, pp.289-296, 2005. ,
Integrins, Cell, vol.110, issue.6, pp.673-687, 2002. ,
Vascular cell adhesion molecule 1 (CD106): A multifaceted regulator of joint inflammation, Arthritis & Rheumatism, vol.44, issue.5, pp.985-994, 2001. ,
Regulation of VCAM-1 Gene Expression in Inflammation ,
Eau disponible pour l'utilisation, 2017. ,
La fibronectine : propriétés et fonctions de la molécule native et de ses fragments, médecine/sciences, vol.13, issue.5, p.657, 1997. ,
Fibronectin and Other Adhesive Glycoproteins, The Extracellular Matrix: an Overview, pp.41-75, 2010. ,
, Biology of Extracellular Matrix). Disponible sur, pp.41-75, 2011.
Junctional adhesion molecules (JAMs): more molecules with dual functions?, Journal of Cell Science, vol.117, issue.1, pp.19-29, 2004. ,
Junctional Adhesion Molecules (JAMs): The JAM-Integrin Connection, Cells, vol.7, issue.4, p.25, 2018. ,
Madcam-1 Expression and Regulation in Murine Colonic Endothelial Cells in Vitro, Inflammatory Bowel Diseases, vol.11, issue.3, pp.258-264, 2005. ,
How Natalizumab Binds and Antagonizes ?4Integrins, Journal of Biological Chemistry, vol.288, issue.45, pp.32314-32325, 2013. ,
Cell biotinylation provides a sensitive and effective detection technique for cellular adhesion assays: comparison with existing methods, Journal of Immunological Methods, vol.253, issue.1-2, pp.57-68, 2001. ,
Measuring the Lifetime of Bonds Made between Surface-linked Molecules, Journal of Biological Chemistry, vol.270, issue.44, pp.26586-26592, 1995. ,
Measuring the Lifetime of Bonds Made between Surface-linked Molecules, Journal of Biological Chemistry, vol.270, issue.44, pp.26586-26592, 1995. ,
Motion of cells sedimenting on a solid surface in a laminar shear flow, Biophysical Journal, vol.61, issue.1, pp.204-215, 1992. ,